News Quantified

DARE – dare bioscience, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

-3.4%

BEAT

7.3%

BEAT

0.0%

BEAT

Form 8-K Dare Bioscience, Inc. For: Mar 02

Form 4 Dare Bioscience, Inc. For: Feb 18 Filed by: JOHNSON SABRINA MARTUCCI

Form 4 Dare Bioscience, Inc. For: Jan 30 Filed by: JOHNSON SABRINA MARTUCCI

Form 4 Dare Bioscience, Inc. For: Jan 30 Filed by: Haring-Layton MarDee

Form 8-K Dare Bioscience, Inc. For: Jan 23

Top News Gainers

2/21 Form SC 13D/A Dare Bioscience, Inc. Filed by: Dare Bioscience, Inc. 19.1%

1/15 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 15.1%

10/14 Daré Bioscience to Participate in Two Upcoming Investor Conferences 14.2%

2/6 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates 13.9%

3/9 Form 3 Dare Bioscience, Inc. For: Mar 06 Filed by: Fair John A 9.8%

4/14 Form SEC STAFF LETTER Dare Bioscience, Inc. 6.4%

5/1 Form S-1 Dare Bioscience, Inc. 4.7%

3/16 Form 8-K Dare Bioscience, Inc. For: Mar 16 4.4%

11/14 Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update 4.2%

8/12 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis 4.1%

Top News Decliners

11/21 Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform -16.7%

4/28 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $7.50 price target on the stock. -16.0%

1/30 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule -14.4%

11/12 Form 10-Q Dare Bioscience, Inc. For: Sep 30 -13.6%

5/8 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research -12.9%

12/18 Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study -12.7%

9/11 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock. -12.2%

1/23 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%

4/1 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® -10.5%

9/11 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics -10.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day